Harrow, Inc. (HROW) Stock Price & Analysis

Harrow, Inc. (HROW) fell 8.19% to USD 38.45 as of July 25, 2026 at 10:02 UTC, according to Nexqual real-time market data.

HROW last closed at USD 41.88; the session ranged USD 38.11–42.3 on volume of 872,157 shares. Market capitalization is $1.43B, with a 52-week range of USD 28.54–54.85 (NGM). Source: Nexqual, July 25, 2026 at 10:02 UTC.

Key Statistics (as of July 25, 2026 at 10:02 UTC)

Technical Analysis (HROW)

Nexqual's technical model rates HROW "NEUTRAL" based on 3 bullish and 4 bearish signals across 125 daily candles, as of July 25, 2026 at 10:02 UTC.

Analyst Ratings (HROW)

Wall Street analysts rate HROW "Strong Buy" based on 8 analysts, with a mean price target of USD 67.75 (range USD 59–88), per Nexqual as of July 25, 2026 at 10:02 UTC.

Earnings (HROW)

Recent Earnings History

Source: Nexqual, July 25, 2026 at 10:02 UTC.

Financials & Fundamentals (HROW)

Source: Nexqual, July 25, 2026 at 10:02 UTC.

Financial Health Score (HROW)

Nexqual rates Harrow, Inc.'s overall financial health "Mixed" across five dimensions, as of July 25, 2026 at 10:02 UTC.

Ownership (HROW)

Source: Nexqual, July 25, 2026 at 10:02 UTC.

Leadership (HROW)

Harrow, Inc. is led by Mark L. Baum (age 53), CEO, Chairman of the Board & Founder, per Nexqual as of July 25, 2026 at 10:02 UTC.

Major Backers & Investors (HROW)

Notable institutional backers of Harrow, Inc. include Opaleye Management Inc., Private Capital Management, LLC, Luxor Capital Group, LP, according to Nexqual as of July 25, 2026 at 10:02 UTC.

Active Investors

Index Funds (Passive)

Source: Nexqual, July 25, 2026 at 10:02 UTC.

From Harrow, Inc.'s Latest SEC 10-K Filing (filed 2026-03-02)

Key Strengths & Strategy (as disclosed to the SEC)

• As a potential FDA-approved successor, MELT-300 is a patented, sublingually delivered formulation of a fixed dose of midazolam (3mg) and ketamine (50mg) designed to provide rapid, predictable sedation without the need for intravenous administration.
• We do, however, believe that our drug candidates and drug products could have commercial appeal in international markets, and have engaged distributors and entered into out-licensing arrangements for certain of our products and proprietary formulations in certain non-U.S. markets, including Canada.
• Manufacturers, including us, are required to report average sales price information to the Centers for Medicare & Medicaid Services ("CMS") on a quarterly basis.
• As a condition of approval, the FDA or other regulatory authorities may require further studies, including Phase 4 post-marketing studies, to provide additional data.

Partnerships

• In addition, inventions relevant to us could be developed by a person not bound by an invention assignment agreement with us, in which case we may have no rights to use the applicable invention.   The following table lists some of our outstanding material patents in the U.S. covering certain branded products we own commercial rights to, general subject matter and latest expiry date.
• For over a decade, we have partnered with U.S. eyecare professionals to develop a comprehensive portfolio of high-quality products used to manage ophthalmic conditions affecting both the front and back of the eye, such as dry eye disease, wet (or neovascular) age-related macular degeneration, cataracts, refractive errors, glaucoma, and a range of other ocular surface conditions and retina diseases.

Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.

Peers & Related Stocks

Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: July 25, 2026 at 10:02 UTC. This page is informational and not investment advice.